iX Biopharma Ltd. (SGX: 42C)
Singapore
· Delayed Price · Currency is SGD
0.0240
-0.0010 (-4.00%)
At close: Nov 12, 2024
iX Biopharma Revenue
In the fiscal year ending June 30, 2024, iX Biopharma had annual revenue of 5.96M SGD with 0.78% growth. iX Biopharma had revenue of 3.29M in the half year ending June 30, 2024, with 172.78% growth.
Revenue
5.96M
Revenue Growth
+0.78%
P/S Ratio
2.96
Revenue / Employee
141.88K
Employees
42
Market Cap
20.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 5.96M | 46.00K | 0.78% |
Jun 30, 2023 | 5.91M | -8.48M | -58.91% |
Jun 30, 2022 | 14.39M | 12.65M | 724.64% |
Jun 30, 2021 | 1.75M | 760.00K | 77.16% |
Jun 30, 2020 | 985.00K | 314.00K | 46.80% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DBS Group Holdings Ltd | 21.21B |
Oversea-Chinese Banking Corporation Limited | 13.66B |
United Overseas Bank Limited | 13.32B |
Singapore Telecommunications Limited | 14.05B |
Wilmar International Limited | 88.86B |
Singapore Airlines Limited | 19.35B |